ABVC BioPharma Receives $450,000 in Q3 Licensing Payments From OncoX Partnership
TL;DR
ABVC BioPharma gains a strategic edge with $450,000 in Q3 licensing payments from OncoX, securing future cash, equity, and royalties in the growing $469 billion cancer market.
ABVC receives $650,000 to date under its agreement with OncoX, which includes $2.5 million in cash, 5 million shares, and royalties based on future net sales.
ABVC's partnership with OncoX advances botanical-derived therapies for four cancer types, potentially improving global health outcomes in a rapidly expanding treatment market.
ABVC's oncology pipeline targets triple-negative breast cancer and other major indications with FDA-approved botanical drugs, leveraging a $105 million partnership value.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma has received $450,000 in licensing payments from OncoX BioPharma during the third quarter of 2025, including $350,000 received in August. These payments are part of a broader licensing agreement that includes $2.5 million in total cash payments, 5 million OncoX shares, and future royalties based on net sales.
The partnership covers four oncology indications that have received FDA Investigational New Drug approvals: triple negative breast cancer, non-small cell lung cancer, myelodysplastic syndromes, and pancreatic cancer. This collaboration positions ABVC to capitalize on the rapidly growing global cancer therapeutics market, which was valued at approximately $194.67 billion in 2024 and is projected to reach $469.38 billion by 2034, according to industry research from Precedence Research.
To date, ABVC has received $650,000 in cash payments, with $1.85 million remaining receivable. The company also holds 5 million OncoX shares. When considering ABVC's subsidiary BioLite, the total entitlement increases to $3.75 million in cash consideration and 7.5 million OncoX shares. The consolidated value of this partnership exceeds $41 million, excluding potential royalty streams.
The significance of this development lies in the validation of ABVC's botanical-derived oncology drug candidates and the immediate financial liquidity it provides for further clinical development. The partnership demonstrates how strategic alliances can accelerate the commercialization of innovative cancer therapies while providing near-term revenue streams for clinical-stage biopharmaceutical companies.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the payments demonstrate the execution strength of their collaboration. The OncoX Chief Executive Officer added that their partnership reflects a vision of combining innovation with strategic collaborations to create long-term value, particularly given the substantial growth projected in the global cancer therapeutics market.
This licensing agreement represents a significant milestone in ABVC's strategy to advance botanical-derived oncology therapeutics toward global commercialization while securing both immediate financial benefits and long-term equity value through their partnership with OncoX.
Curated from NewMediaWire
